SEC Filing Summary: AIT Therapeutics, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AIT Therapeutics, Inc. on August 16, 2017, reporting events occurring on August 11, 2017. The registrant is a Delaware corporation and an emerging growth company. The filing serves to announce financial results for the quarter ended June 30, 2017, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is furnished but not filed as part of this text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of the Q2 2017 results.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information in this Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the full text of the press release issued on August 11, 2017 (Exhibit 99.1).
- Confirm the company's status as an emerging growth company and any implications for financial reporting standards.
- Note that the financial data in this 8-K is not legally "filed" under Section 18 of the Exchange Act, limiting liability protections for the disclosed numbers.
- Check for any subsequent filings that may incorporate the press release by reference.